CD40 and neoplasm: Yang and colleagues demonstrated that the combination of IL-6 inhibition with CD40 stimulation reversed M2-mediated tumor immunosuppression, sensitized tumors to checkpoint blockade, and extended animal survival in two syngeneic GBM models [39].